The Indian pharmaceutical industry, often hailed as the “pharmacy of the world,” is currently navigating a challenging scenario as the United States debates imposing tariffs on pharmaceutical imports. President Donald Trump’s announcement of potential 25% or higher tariffs could reshape the dynamics of the global pharmaceutical trade, with significant implications for both economies. Despite this looming uncertainty, Indian drugmakers demonstrate optimism, underpinned by their competitive pricing, quality, and global market dominance.
The U.S.-India Pharmaceutical Trade Relationship
India is a major supplier of generic drugs, which are critical for the U.S. healthcare system’s cost efficiency. Generic medicines, often 50% to 90% cheaper than branded alternatives, accounted for savings of approximately $408 billion in 2022 for the U.S. healthcare sector. Indian companies like Sun Pharma, Dr. Reddy’s, Cipla, and Zydus Lifesciences dominate the generics market, supplying nearly 65% of all generic drugs in the U.S. These exports soared to $9 billion last fiscal year, reflecting a 16% annual growth.
India imposes a 10% tariff on U.S. pharma imports, whereas Indian drugmakers benefit from minimal tariffs in the U.S. Despite this advantageous framework, proposed tariff hikes could unsettle the balance, impacting margins and potentially leading to healthcare inflation in the U.S.
The Competitive Edge of Indian Pharma
Industry experts and trade bodies, such as the Pharmaceuticals Export Promotion Council of India (Pharmexcil), remain confident that Indian manufacturers can sustain their dominant position in the U.S. market even under new tariff conditions. Their competitive edge lies in offering high-quality generics at unparalleled affordability. Raja Bhanu, Director General of Pharmexcil, has expressed confidence that India’s pricing and efficiency advantages will enable its pharma companies to adapt.
However, any failure to pass on increased costs to consumers could threaten the thin profit margins—often as low as 15%—of Indian companies. Analysts caution that this may force companies to withdraw certain products, causing potential shortages in the U.S. market and spiking drug prices.
Potential Impact on the U.S.
A significant concern for the U.S. healthcare system is its reliance on Indian drugmakers to meet demand. The foundation of affordable healthcare in the U.S. rests heavily on generics, and any disruption in supply could lead to severe shortages. Experts argue that the U.S. lacks the manufacturing infrastructure to quickly replace the scale of India’s pharmaceutical production.
Higher tariffs could make Indian drugs less competitive, and Indian companies may rationalize portfolios or exit some market segments, further compounding challenges for the U.S. healthcare system.
Industry Efforts and Negotiations
Indian pharmaceutical leaders hope bilateral negotiations will ease tensions. Sudarshan Jain, Secretary General of the Indian Pharmaceutical Alliance, emphasized the importance of ongoing dialogue between India and the U.S. The Indian government is also expected to advocate for an exception, highlighting the inflationary impact tariffs could have on U.S. healthcare.
Sun Pharma, India’s largest drugmaker, has already announced its intention to pass on any additional costs directly to consumers, indicating the impact may not solely burden Indian manufacturers.
Broader Implications
Beyond generics, the Indian pharmaceutical industry is also emerging as a leader in peptides, oligonucleotide-based treatments, and other innovative therapies. With global markets for these therapies expected to grow significantly, Indian pharma companies remain well-positioned to diversify and expand into these lucrative domains.
-Raja Aditya
